Codagenix

No. 467: In which law firms and the universe expand, and offshore wind goes to school

  Well played: You’ve done it again, dear reader – the workweek is winding down and a well-earned (if wintry) weekend awaits. Butter believe it: It’s Jan. 17 out there, and here’s a toast to your efforts – celebrating one of the oldest blended beverages in mixological history, today is National Hot Buttered Rum Day. Not to mention National Bootlegger’s Day. Shirley Temples for you: They’re too young for booze, but raise a glass anyway…


Codagenix scores big with $20M Series B round

By GREGORY ZELLER // A stellar $20 million investment round has blasted a Long Island biotech into the stratosphere, and a new tax bracket. Farmingdale-based Codagenix Inc., a 2012 startup launched by Stony Brook University assistant research professor Steffan Mueller and Farmingdale State College biology professor J. Robert Coleman, has closed a $20 million Series B investment round, led by Adjuvant Capital, a New York City/San Francisco venture capital firm focused on life sciences. Also…


Matching state grants boost regional SBIR innovators

A Stony Brook University-based small-biz booster program is doubling down on federal Small Business Innovation Research award winners. Through a $1.2 million Empire State Development Corp. incentives package administered by the university’s Small Business Development Center and the Research Foundation for SUNY, SBU has released the first set of matching grant funds to SBIR awardees in Nassau and Suffolk counties. Four regional companies benefited from a total of $50,000 released this round, including Farmingdale-based vaccination…


Topspin finds an inspirational Remedy in NYC

A Long Island-born investment fund with a taste for tech has acquired an award-winning Manhattan-based digital health platform. Topspin Partners, formerly headquartered in Roslyn Heights and now based in Mamaroneck, announced Wednesday that it has taken a controlling interest in Remedy Health Media, a New York City digital specialist known for its inspirational videos and award-winning online brands. Financial terms of the deal were not disclosed. In addition to its popular HealthCentral website, a respected…


Codagenix scores again: $3M to hunt down deadly RSV

By GREGORY ZELLER // A fresh $3 million in public and private investments has set Codagenix Inc. on the trail of another nefarious disease. Already developing vaccines for Zika virus, the mutating menace Influenza A and a host of other viral villains, Codagenix will now focus its vaccine-creation might on Respiratory Syncytial Virus through a $1.5 million Phase II Small Business Innovation Research grant from the National Institutes of Health and another $1.5 million in…


Familiar names abound in Center for Biotech awards

By GREGORY ZELLER // Several breakout research projects – and a few familiar faces from the cutting edge – scored funding this week through Stony Brook University’s annual biotechnology awards program. The Center for Biotechnology at SBU, an Empire State Development Division of Science, Technology and Innovation Center for Advanced Technology, has announced the recipients of the 2017-18 Applied Research and Development awards. The awards, along with matching funds from the recipients and other stakeholders,…


Codagenix: Flu can mutate, but it can’t hide

By GREGORY ZELLER // In a potentially huge breakthrough in the struggle against seasonal influenza mutations, Codagenix Inc. is preparing to release data demonstrating “multi-season efficacy” for its frontline flu vaccine – meaning the vaccine could prevent flu-related sicknesses even after the virus mutates. According to the Farmingdale-based clinical-stage startup, in multiple studies involving pigs and ferrets, CodaVax-H1N1 – Codagenx’s live-attenuated Influenza A vaccine – induced “a robust immune response to multiple seasonal strains of…


LIREDC can’t win ’em all, but finds solace in $62M

By GREGORY ZELLER // While $62 million is nothing to sneeze at, it’s fair to say the Long Island Regional Economic Development Council was hoping for more. The LIREDC – a four-time “Top Performer” in Empire State Development’s annual funding contest, which marked the completion of its sixth round Thursday with an Albany awards ceremony – had submitted an ambitious agenda filled with 112 projects covering biotechnology, synthetics manufacturing, aerospace and half-a-dozen other key industries,…


Codagenix, SUNY RF ink exclusive licensing deal

A year of big steps has led to one giant leap for Codagenix. Stony Brook University, through the Research Foundation for the State University of New York, has entered into an exclusive licensing agreement with the Farmingdale-based biotech to commercialize a platform technology aiming to create a “pipeline of live attenuated vaccines” against viral infections attacking humans and other animals. The exclusive licensing agreement, announced Wednesday, involves technology developed in the laboratory of Eckard Wimmer,…


Codagenix commences Zika vaccine testing

By GREGORY ZELLER // Farmingdale biotech Codagenix Inc. has commenced the first tests of its potential Zika virus vaccines in a living host. In a noteworthy display of speed sure to impress the medical community and potential investors alike, the 2012 startup began in vivo testing of its live-attenuated Zika virus vaccine candidates earlier this month – just 27 days after it plugged Zika into its proprietary, synthetic biology-based vaccine-design platform. The safety and efficacy study…


Some pig: USDA, Codagenix target swine flu

By GREGORY ZELLER // With Zika virus, Foot and Mouth Disease and other global threats already in its crosshairs, Farmingdale biotech Codagenix Inc. is challenging another high-profile opponent: swine flu. A Phase I Small Business Innovation Research grant from the U.S. Department of Agriculture will fund research and development of an influenza vaccine for swine using Codagenix’s proprietary software platform, which “re-codes” viruses to create and test potential vaccines. Research and development under the $99,710…


Move complete, Codagenix takes aim at Zika

By GREGORY ZELLER // Be afraid, Zika virus. With 1,500 square feet of new wet-lab space and buckets of confidence, the big thinkers at Codagenix are targeting your chemical code – with a candidate vaccine likely ready for animal testing inside of six weeks. So says J. Robert Coleman, the Farmingdale State College biology professor who cofounded the 2012 startup with Stony Brook University assistant research professor Steffen Mueller. Zika is a flavivirus – a…


Catching you up on the Zika virus

By GREGORY ZELLER // With one confirmed Zika virus case already recorded and a dozen concerned calls coming every day from pregnant women, Northwell Health has opened its second Zika-focused clinic in as many months. The former North Shore-LIJ Health System this week announced the opening of the Zika in Pregnancy Clinic at North Shore University Hospital in Manhasset. The Pregnancy Clinic won’t do actual Zika virus testing, but will help calm the fears of…


Chembio lands $550K grant for Zika test

Chembio Diagnostics has been awarded a $550,000 “catalyst grant” to develop a rapid test for the Zika virus and similar maladies. The grant comes from Microsoft co-founder Paul G. Allen, who has a long history of supporting Chembio’s research efforts, most recently surrounding the Ebola outbreak. Company officials said Chembio will develop a test to detect Zika alone, and another to detect Zika, dengue and chikungunya viruses. The company also will add Zika to a six-virus…


Codagenix preps for fight against Zika virus

By GREGORY ZELLER // A Stony Brook startup that digitally recreates viruses in order to reprogram their genomes is preparing to take on the Zika virus, which World Health Organization officials said Thursday is “spreading explosively” through the Americas. Codagenix, a 2012 startup cofounded by Farmingdale State College biology professor J. Robert Coleman and former Stony Brook University assistant research professor Steffen Mueller, is keeping a close eye on the migration of the virus, which…